Prognostic significance of prostate specific antigen PSA in patients with non-metastasic carcinoma of the prostate

ABSTRACT

Prostatic carcinomas vary in their biologic potential. Serum prostate specific antigen, stage, tumor grade and Gleason's grade were studied in patients with non-metastatic carcinoma of prostate. Thirty-six patients with non-metastatic carcinoma of prostate were included in this study of stage A2, B or C. Their age range was 57 to 68 years median age of 62 years. All patients were treated by external beam radiation therapy. Serum prostate specific antigen was estimated before treatment and every two-four months post treatment. Thirty-one patients were evaluable for treatment results as five patients did not attend follow up after treatment. Twenty-nine patients had their prostate specific antigen lowered to a normal level after the radiation therapy treatment [<4 ng/ml]. Two patients had lowering of their serum PSA level but to values above 4 ng/ml. The disease free survival at two-years for the whole group was 64%. Pretreatment serum PSA, Gleason's grade and stage were statistically significant predictors of disease free survival